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Forced degradationAbstract A comprehensive stability indicating HPLC with diode array detection method was
developed for determination of the recently approved phosphodiesterase type 4 (PDE-4) inhibitor
roﬂumilast (RFL). Effective chromatographic separation was achieved using Durashell C18 column
(4.6 · 250 mm, 5 lm particle size) with isocratic elution of the mobile phase composed of 0.0065 M
ammonium acetate pH 6.3, methanol and acetonitrile in the ratio of 30:35:35 (by volume). The
mobile phase was pumped at a ﬂow rate of 1.3 mL/min, and quantiﬁcation of RFL was based
on measuring its peak areas at 251 nm. RFL eluted at retention time 6.2 min. Analytical perfor-
mance of the proposed HPLC procedure was thoroughly validated with respect to system suitabil-
ity, linearity, range, precision, accuracy, speciﬁcity, robustness, detection and quantiﬁcation limits.
The linearity range was 2.5–200 lg/mL with correlation coefﬁcient >0.9998. The drug was
subjected to stress conditions of neutral, acidic and alkaline hydrolysis, oxidation, photolysis and
thermal degradation. The proposed method proved to be stability-indicating by resolution of the
drug from its forced degradation products. Moreover, speciﬁcity of the method was veriﬁed by
resolution of drug from more than 20 pharmaceutical compounds of various medicinal categories.
The validated HPLC method was successfully applied to the analysis of the cited drug in its tablet
80 T.S. Belal et al.dosage form. The proposed method made use of DAD as a tool for peak identity and purity con-
ﬁrmation.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
Open access under CC BY-NC-ND license.1. Introduction
Roﬂumilast (RFL) (Fig. 1), chemically known as 3-(cyclopro-
pylmethoxy)-N-(3,5-dichloro-4-pyridyl)-4-(diﬂuoromethoxy)
benzamide,1 is a newly approved selective phosphodiesterase-4
(PDE-4) inhibitor for the treatment of severe chronic obstruc-
tive pulmonary disease (COPD) associated with chronic
bronchitis and a history of exacerbations.2,3 RFL is not yet
an ofﬁcial drug in any of the famous pharmacopoeias, includ-
ing the British Pharmacopoeia, European Pharmacopoeia and
United States Pharmacopoeia. Furthermore, few methods can
be found in the scientiﬁc literature for its analysis. Simulta-
neous quantiﬁcation of RFL and its N-oxide metabolite in
human plasma has been carried out using liquid chromatogra-
phy with tandem mass spectrometry LC–MS/MS methods.4,5
The same technique has been further applied for monitoring
several PDE-4 inhibitors including RFL in sports drug
testing.6 The separation of RFL from its forced degradation
products was addressed in only a single report, which
described the use of RP-HPLC with a multi-step gradient
mobile phase.7 Besides, there was a lack of information about
validation of the method or its application to real pharmaceu-
tical samples.7 Again, RP-HPLC with a multi-step gradient
mobile phase method was reported for the determination of
RFL in only the bulk powder.8 Recently, a UV spectrophoto-
metric method was described for RFL estimation in tablet dos-
age form.9
The objective of this work is to develop a simple, rapid,
selective and reliable HPLC with diode array detection method
for the quantitative analysis of RFL in tablet dosage form. The
method was thoroughly validated and tested for its speciﬁcity
and stability-indicating properties by resolution of RFL from
its forced hydrolytic, oxidative, photolytic and dry heat degra-
dation products. In addition, speciﬁcity of the proposed
method was further investigated by separation of the analyte
from several pharmaceutical compounds from different phar-
macological categories.2. Experimental
2.1. Instrumentation
The HPLC-DAD system consisted of Waters 2695 Alliance
(quaternary pump, vacuum degasser heater, diode array and
multiple wavelength detector Waters 2996) connected to a
computer loaded with MILLENNIUM32 Login Version 4.00
Software. An automated injector model SM7 with loop capac-
ity 100 lL was used. The column used was Durashell-C18
(4.6 · 250 mm, 5 lm particle size) (Bonna-Agela Technologies
Inc., Wilmington, DE, USA). Filtration of solutions prior to
injection to the column was done using cellulose nitrate mem-
brane ﬁlters (0.45 lm pore size) (Sartorius Stedim Biotech
GmbH, Goettingen, Germany).2.2. Materials and chemicals
Roﬂumilast was kindly donated by Pharco Pharmaceuticals
Co., Alexandria, Egypt. HPLC-grade acetonitrile (Carbon
Group Ringaskiddy, Cork, Ireland), HPLC-grade methanol
(Lab-scan, Gliwice, Poland), HPLC-grade glacial acetic acid
(Scharlau Chemie S.A., Sentmenat, Spain), reagent grade
ammonium acetate (Scharlau Chemie S.A., Sentmenat, Spain),
analytical grade of hydrochloric acid (BDH Laboratory Sup-
pliers, Poole, England), sodium hydroxide (El-Nasr Pharma-
ceutical Chemicals Co., Egypt), 50% hydrogen peroxide
(Chemajet Chemical Co., Egypt) and high purity distilled
water were used. Pharmaceutical formulation assayed in the
study was Dalivent tablets (Pharco Pharmaceuticals Co.,
Alexandria, Egypt) labeled to contain 0.5 mg RFL per tablet.
2.3. General procedure
2.3.1. Chromatographic conditions
A mobile phase system consisting of 0.0065 M ammonium ace-
tate pH 6.3, acetonitrile and methanol in the ratio of 30:35:35
(by volume) was used. The separation was achieved with iso-
cratic elution. The ﬂow rate was 1.3 mL/min. The injection
volume was 35 lL. The eluant was monitored by the diode
array detector (DAD) from 190 to 400 nm, and chromato-
grams were extracted at 251 nm. All determinations were per-
formed at 30 C.
2.3.2. Standard solutions and construction of the calibration
curve
RFL stock solution (500 lg/mL) was prepared in HPLC-grade
methanol. The working standard solutions were prepared by
dilution of aliquots of the stock solution with the mobile phase
to reach the concentration range 2.5–200 lg/mL. Triplicate
injections were made for each concentration and chromato-
graphed under the previously described chromatographic con-
ditions. Peak areas were plotted against the corresponding
concentrations to construct the calibration graph; in addition,
the linear regression equation was calculated.
2.4. Assay of commercial tablets
Ten Dalivent tablets were accurately weighed and ﬁnely
powdered. An accurate weight of the powdered tablets equiva-
lent to 1.25 mg RFL was extracted into 25 mL mobile phase
with the aid of sonication for 10 min then ﬁltered into a
50 mL-volumetric ﬂask. The residue was washed with
2 · 10 mL portions of the mobile phase, washings were added
to the ﬁltrate and ﬁnally the solution was completed to volume
with the mobile phase. The prepared sample solution was chro-
matographed using the previously described conditions. Recov-
ered concentrations were calculated from the corresponding
external standard (simultaneously prepared standard RFL
solution).
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Figure 1 Chemical structure of roﬂumilast (RFL).
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solution with a portion of RFL stock standard solution to
obtain total concentration within the previously speciﬁed
range then treated as previously described. Recovered concen-
tration was calculated by comparing the drug response in
tablet solution with the increment response obtained after
addition of the standard.
2.5. Preparation of forced-degradation solutions
Forced degradation studies were carried out on RFL standard
according to the following conditions:
2.5.1. Neutral (water) degradation
RFL solutions were treated with 5 mL of distilled water. Solu-
tions were placed in a water bath at 90 C for 6 h, then they
were diluted to volume with the mobile phase to obtain a ﬁnal
concentration of 25 lg/mL.
2.5.2. Acidic and basic degradation
RFL solutions were treated with 2 mL of 1 M hydrochloric
acid solution or 1 M sodium hydroxide solution. Solutions
were placed in a water bath at 90 C for 1 h. After the speciﬁed
time interval, all solutions were neutralized by adjusting the
pH to 7.0 and then diluted to volume with the mobile phase
to obtain a ﬁnal concentration of 25 lg/mL.
2.5.3. Oxidative degradation
RFL solutions were treated with 5 mL of H2O2 5% solution.
Solutions were placed in a water bath at 90 C for 1 h and
5 h. After the speciﬁed time intervals, solutions were diluted
to volume with the mobile phase to obtain a ﬁnal concentra-
tion of 25 lg/mL.
2.5.4. Photolytic degradation
An amount of RFL powder (100 mg) was subjected to UV
irradiation (200 W h/m2) for 6 h. After the speciﬁed time, the
drug powder was dissolved in methanol, and aliquots of the
methanolic stock were diluted to volume with the mobile phase
to obtain a ﬁnal concentration of 25 lg/mL.
2.5.5. Dry heat degradation
An amount of RFL powder (100 mg) was kept in an oven at
120 C for 8 h. After the speciﬁed time, the powder was dis-
solved in methanol, and aliquots of the methanolic stock were
diluted to volume with the mobile phase to obtain a ﬁnal con-
centration of 25 lg/mL.
After the previous treatments, all forced degradation solu-
tions were ﬁltered with a 0.45 lm membrane ﬁlter prior to
injection to the column.3. Results and discussion
3.1. Optimization of chromatographic conditions
An isocratic liquid chromatographic method coupled with
diode array detection was developed to provide a suitable
and reliable procedure for the routine quality control analysis
of RFL. The developed method was carefully designed and
optimized to separate the cited drug from its forced degrada-
tion products as well. The most important aspect in LC
method development is the achievement of sufﬁcient resolution
of the target drug from all other compounds present in the
sample with acceptable peak symmetry in a reasonable analysis
time. To achieve this goal, several experiments were carried out
to optimize both the stationary and mobile phases. For optimi-
zation of the stationary phase, several reversed phase columns
(Thermo-C18 (4.6 · 250 mm), Waters-C18 (4.6 · 250 mm) and
Durashell-C18 (4.6 · 250 mm) were tested. The best clear sep-
aration between all the eluting peaks (RFL and its degradation
products), better system suitability parameters, symmetric
RFL peak and relatively short retention time were attained
using the Durashell-C18 column; hence, it became the column
of choice for this study.
Several mobile phases were evaluated using various propor-
tions of different aqueous phases and organic modiﬁers. The
best mobile phase combination was 0.0065 M ammonium ace-
tate pH 6.3, methanol and acetonitrile in the ratio 30:35:35 (by
volume). Methanol alone was tried as an organic modiﬁer and
ammonium acetate solution was substituted by other aqueous
phases such as water. In these trials, RFL suffered from
increased retention time and some chromatograms showed
broad peaks and/or unresolved peaks. The mixed mobile phase
was used as ﬁnal dilution solvent for all working solutions
since it resulted in more decent chromatograms and sharper
peaks than those obtained upon using methanol or acetonitrile
alone. Flow rate was kept constant at 1.3 mL/min and column
temperature was adjusted at 30 C.
The diode array detector (DAD) enhances the power of
HPLC and is an elegant option for assessing method speciﬁcity
by monitoring the recorded spectra during peak elution. The
multiple wavelength detection offers the advantage of measur-
ing the analyte at its maximum wavelength, thus improving
sensitivity. RFL exhibits considerable absorption all over the
range 200–310 nm with two maxima at 213 and 251 nm of
which the latter was chosen. Accordingly, all chromatograms
in this study were recorded at 251 nm. Quantiﬁcation was
based on peak area measurement. The previously described
chromatographic conditions showed well-deﬁned symmetric
RFL peak at about 6.24 ± 0.005 min. Fig. 2 shows a typical
chromatogram for RFL using the optimized conditions.
Retention factor (k0) is 5.25, tailing factor is 1.04 and column
performance (apparent efﬁciency) expressed by the number of
theoretical plates (N) is 9631.
3.2. Stability-indicating aspects
Forced degradation experiments were carried out on standard
RFL to produce the possible relevant degradation products
and test their chromatographic behavior using the developed
method. Hydrolytic, using neutral (water), strong acidic (1 M
HCl) and strong basic (1 M NaOH) media, oxidative (5%
Figure 2 Representative HPLC chromatogram of RFL (25 lg/mL).
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conducted, and the resulting chromatograms were compared
with those obtained from a standard untreated solution of
the drug. No strong signs of degradation of RFL were
observed after heating for 6 h at 90 C in neutral conditions.
RFL peak appeared at its speciﬁc retention time with an area
almost identical (97.8%) to that of a standard of the same con-
centration and only small extra peaks at 2.81 and 8.29 min
were observed (Fig. 3a). The situation was quite different in
case of degradation under acidic conditions. About 33%
decrease in the parent drug peak area as well as the appearance
of new peaks for degradation products at 2.94, 3.32, 3.72 and
8.27 min was clearly noticed after heating with 1 M HCl solu-
tion at 90 C for 1 h (Fig. 3b). Resolution was calculated
between RFL and both the preceding and successive degrada-
tion peaks at 3.72 and 8.27 min, respectively. Resolution was
found not less than 7.69 which implied an adequate baseline
separation between RFL and either of its nearest degradation
peaks. Likewise in case of degradation under basic conditions,
about 18.5% decrease in the parent drug peak area as well as
the appearance of new peaks for degradation products at 2.13,
2.81, 3.34 and 4.83 min was clearly detected after heating with
1 M NaOH solution at 90 C for 1 h (Fig. 3c). Excellent reso-
lution (Rs = 6.23) was observed between RFL and its nearest
degradation peak at 4.83 min. Oxidative degradation with 5%
H2O2 at 90 C for 1 h revealed almost intact RFL peak. On the
other hand, heating with the same reagent at 90 C for 5 h
caused about 26.4% reduction in the peak area of RFL. Sev-
eral degradation peaks can be seen in the chromatogram at
retention times 2.92, 3.31, 3.80, 4.18, 4.55, 4.93, 5.71 and
7.80 min (Fig. 3d). Again, resolution was calculated between
RFL and the preceding degradation peak at 5.71 min, and it
was found 1.78 which implied an adequate baseline separation
between the two successive peaks. Irradiation of RFL powder
with UV light for 6 h caused no signiﬁcant change in the peak
area of the parent compound. Fig. 3e shows the chromatogram
of RFL after UV photolytic degradation and two well-resolved
small extra peaks at 2.79 and 10.77 min are detected. Finally,
RFL was found stable under thermal (dry heat) degradation
conditions. Its peak appeared at its speciﬁc retention time with
an area comparable to that of standard of the same concentra-
tion, and the chromatogram did not show any extra peaks
(Fig. 3f). These results are in agreement with the previousstudy which indicated that RFL is stable to thermal and pho-
todegradation.7 In all these forced degradation experiments,
RFL was successfully separated from the degradation prod-
ucts as conﬁrmed by the resolution values calculated for each
chromatogram (Rs > 1.5). Results of the forced degradation
of RFL in different conditions are summarized in Table 1.
RFL Peak purity was checked in all the forced degradation
chromatograms by using the diode array detector. Purity angle
is a measure of spectral homogeneity. It is the weighted aver-
age of all Spectral Contrast Angles calculated by comparing
the spectra from all data points in the integrated peak against
the peak apex spectrum. If the purity angle is less than the cal-
culated threshold angle, the peak is spectrally homogeneous. If
the purity angle is greater than the calculated threshold angle,
there is something within the peak that cannot be explained by
noise, and consequently the peak is considered impure or not
spectrally homogeneous. The obtained purity angles were
within the purity threshold limits which conﬁrm that RFL
peaks are homogenous and pure in all the analyzed samples
subjected to forced degradation conditions (Fig. 4).
3.3. Validation of the proposed method
The proposed HPLC method was validated as per the Interna-
tional Conference on Harmonization (ICH) guidelines on val-
idation of analytical procedures.10
3.3.1. Linearity and concentration range
The linearity of the proposed HPLC procedure was evaluated
by analyzing a series of different concentrations for the ana-
lyte (n= 14). The linear regression equation was generated
by least squares treatment of the calibration data. Under
the optimized conditions described above, the measured peak
areas were found perfectly proportional to concentrations of
RFL (Fig. 5). Table 2 presents the analytical parameters
including linear regression equation, concentration range,
correlation coefﬁcient, standard deviations of the intercept
(Sa), slope (Sb) and standard deviations of residuals (Sy/x).
Regression analysis shows good linearity as indicated from
the correlation coefﬁcient values (>0.9998). In addition,
deviation around the slope can be further evaluated by calcu-
lating the RSD% of the slope (Sb%) which was found to be
Figure 3 HPLC chromatograms of RFL (25 lg/mL) after exposure to neutral (a), acid (b), base (c), oxidative (d), photolytic UV (e) and
thermal dry heat degradation (f).
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analysis of variance (ANOVA) test. The most important sta-
tistic in this test is the F-value which is the ratio of the mean
of squares due to regression divided by the mean of squares
due to residuals. High F value reveals an increase in the mean
of squares due to regression and a decrease in the mean of
squares due to residuals. The greater the mean of squaresdue to regression, the steeper is the regression line. The smal-
ler the mean of squares due to residuals, the less is the scatter
of experimental points around the regression line. Conse-
quently, regression lines with high F values (low signiﬁcance
F) are much better than those with lower ones. Good regres-
sion lines show high values for both r and F statistical
parameters.
Figure 3 (continued)
84 T.S. Belal et al.3.3.2. Detection and quantiﬁcation limits
The limit of detection (LOD) is deﬁned as the concentration of
the analyte which has a signal-to-noise ratio of 3:1. For the
limit of quantiﬁcation (LOQ), the ratio considered is 10:1.
The LOD and LOQ values of RFL were calculated using the
signal-to-noise ratio method and are given in Table 2. Both
LOD and LOQ values conﬁrm the sensitivity of the proposed
HPLC method.3.3.3. Accuracy and precision
The within-day (intra-day) precision and accuracy for the
proposed method were studied at four concentration levels
for RFL using three replicate determinations for each
concentration within 1 day. Similarly, the between day
(inter-day) precision and accuracy were tested by analyzing
the same four concentrations using three replicate determi-
nations repeated on 3 days. Recoveries were calculated using
Table 1 Summary of the degradation results of RFL.
Degradation type Degradation conditions % Remaining of RFL Retention times of the degradation peaks (min)
Neutral (water) 90 C for 6 h 97.8 2.81, 8.29
Acidic (1 M HCl) 90 C for 1 h 67.0 2.94, 3.32, 3.72, 8.27
Basic (1 M NaOH) 90 C for 1 h 81.5 2.13, 2.81, 3.34, 4.83
Oxidation (5% H2O2) 90 C for 5 h 73.6 2.92, 3.31, 3.80, 4.18, 4.55, 4.93, 5.71, 7.80
Photo-degradation UV irradiation for 6 h 98.0 2.79, 10.77
Thermal (dry heat) 120 C for 8 h 98.5 –
Purity Angle = 0.067 
Purity Threshold = 0.280 
a
Purity Angle = 0.068 
Purity Threshold = 0.279 
b
Purity Angle = 0.060 
Purity Threshold = 0.263 
c
Figure 4 Purity plots of RFL after exposure to neutral (a), acid (b), base (c), oxidative (d), photolytic UV (e) and thermal dry heat
degradation (f).
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satisfactory. The percentage relative standard deviation
(RSD%) and percentage relative error (Er%) did not exceed1.1% proving the high precision and accuracy of the devel-
oped method for estimation of the analyte in its bulk form
(Table 3).
Purity Angle = 0.062 
Purity Threshold = 0.273 
d
Purity Angle = 0.058 
Purity Threshold = 0.269 
e
Purity Angle = 0.068 
Purity Threshold = 0.278 
f
Figure 4 (continued)
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Speciﬁcity is deﬁned as the ability to access unequivocally the
analyte in the presence of components that may be expected to
be present, such as impurities, degradation products and
matrix components.10 Method speciﬁcity was already demon-
strated by the successful resolution of the intact drug from
its forced degradation products. DAD played a crucial role
to conﬁrm the purity of RFL peaks in all forced degradation
chromatograms (Figs. 3 and 4). Moreover, to judge the speci-
ﬁcity of the proposed method, several pharmaceutical com-
pounds of different pharmacological categories were tested
to examine their retention properties and their resolution from
the target compound. This approach to test the speciﬁcity of
an HPLC method has been already applied in previous
studies.11,12More than 20 compounds were found completely separated
from the drug under analysis. Resolution was calculated
between RFL and its nearest preceding or successive peaks.
Resolution was found not less than 9.53 which implies an ade-
quate baseline separation between the analyte and the added
compounds. Table 4 lists the separated compounds along with
their retention time values. Fig. 6 shows an example chromato-
gram for the separation of RFL together with several added
pharmaceutical compounds.
3.3.5. Robustness
The robustness of an analytical procedure is a measure of its
capability to remain unaffected by small but deliberate varia-
tions in method parameters and provides an indication of its
reliability during normal usage.10 Robustness was examined
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Figure 5 Calibration curve for RFL analysis.
Table 2 Analytical parameters for the determination of RFL
using the proposed HPLC-DAD method.
Parameter Result
Wavelength (nm) 251
Concentration range (lg/mL) 2.5–200
Intercept (a) 39999.1
Sa 20871.6
Slope (b) 48784.9
Sb 210.3
RSD% of the slope 0.43
Correlation coeﬃcient (r) 0.99989
Sy/x 50982.9
F 53813.1
Signiﬁcance F 2.77 · 1023
LOD (lg/mL) 0.56
LOQ (lg/mL) 1.87
Table 4 Retention times of the tested pharmaceutical
compounds using the proposed method.
Compound Retention time (min)
Pheniramine maleate 1.72 and 2.75
Chlorpheniramine maleate 1.72 and 3.52
Dimethindene maleate 1.70 and 3.89
Ketotifen fumarate 1.57 and 4.55
Clemastine maleate 1.65 and 8.80
Salbutamol sulfate 1.97
Terbutaline sulfate 1.97
Dexamethazone sodium phosphate 2.09
Theophylline 2.10
Aminophylline 2.10
Formotrol fumarate 2.32
Guaifenesin 2.38
Fexofenadine HCl 2.65
Prednisone 2.88
Prednisolone 3.09
Cetirizine HCl 3.67
Desloratadine HCl 3.76
Zaﬁrlukast 4.30
Loratadine HCl 14.52
Montelukast sodium 27.27
Ebastine 42.67
HPLC-DAD method for determination of the phosphodiesterase (PDE-4) inhibitor roﬂumilast 87by making small changes in acetonitrile or methanol content in
the mobile phase (±2%), ﬂow rate (±0.05 mL/min), column
temperature (±5 C), pH of ammonium acetate solution
(±0.3) or working wavelength (±2 nm) and recording the
chromatograms of RFL standard solution. These variations
did not have signiﬁcant effects on the measured response (peak
area) or retention time of RFL. Recoveries obtained were
acceptable (99.4–102%), and RSD% values did not exceed
3.6%. Table 5 shows the effects of the studied variations on
the percentage recoveries and retention time of RFL.Table 3 Precision and accuracy for the determination of RFL in b
Nominal value (lg/mL) Within-day
Found ± SDa (lg/mL) RSD (%)
12.5 12.51 ± 0.03 0.24
25 25.19 ± 0.09 0.36
50 49.62 ± 0.24 0.48
150 150.49 ± 0.48 0.32
a Mean ± standard deviation for three determinations.3.3.6. Stability of solutions
The stability of RFL working solutions as well as sample
solutions in the mobile phase was examined, and no chromato-
graphic changes were observed within 9 h at room tempera-
ture. Also, the stock solutions prepared in HPLC-grade
methanol were stable for at least 1 week when stored under
refrigeration at 4 C. Retention times and peak areas of the
drug remained unchanged and no signiﬁcant degradation
was observed during these periods.
3.4. Assay of RFL in tablets
The developed method was applied for the assay of the drug in
its commercial pharmaceutical formulation (Dalivent tab-
lets). An accurate amount of the tablets powder was extracted
into the mobile phase and an aliquot of the tablet extract was
directly injected to the column. The active ingredient eluted at
its speciﬁc retention time, and no interfering peaks were
observed from any of the excipients of the assayed tablets.
The diode array detection enables peak purity veriﬁcation
where no signs of co-elution from any of the excipients were
detected (Fig. 7). Recoveries were calculated using both exter-
nal standard and standard addition methods. Assay resultsulk form using the proposed method.
Between-day
Er (%) Found ± SD
a (lg/mL) RSD (%) Er (%)
0.08 12.53 ± 0.09 0.72 0.24
0.76 25.15 ± 0.19 0.76 0.60
0.76 49.62 ± 0.41 0.83 0.76
0.33 150.15 ± 1.64 1.09 0.10
Figure 6 Representative chromatogram of a mixture containing (1) maleate, (2) theophylline, (3) guaifenesin, (4) pheniramine, (5)
cetirizine HCl, (6) zaﬁrlukast, (7) RFL, (8) loratadine HCl and (9) montelukast.
Table 5 Robustness evaluation for the determination of RFL using the proposed HPLC-DAD method.
Parameter % Recovery ± SDa RSD% Retention time ± SD
Methanol ratio in mobile phase 99.42 ± 0.74 0.74 6.264 ± 0.64
±2%
Acetonitrile ratio in mobile phase 99.45 ± 0.73 0.73 6.289 ± 0.73
±2%
Column temperature 100.47 ± 0.70 0.70 6.235 ± 0.25
30 ± 5 C
Flow rate 100.74 ± 3.58 3.55 6.238 ± 0.19
1.3 ± 0.05 mL/min
Wavelength 99.45 ± 0.69 0.69 6.243 ± 0.002
251 ± 2 nm
pH 101.94 ± 1.26 1.24 6.237 ± 0.005
6.3 ± 0.3
a Mean ± standard deviation for 3 determinations.
Purity Angle = 0.066 
Purity Threshold = 0.272 
Figure 7 Purity plot of RFL in its commercial dosage form (Dalivent tablets).
88 T.S. Belal et al.revealed satisfactory accuracy and precision as indicated from
% recovery, SD and RSD% values (Table 6). Furthermore, a
previously published UV spectrophotometric method was
applied as a comparison method for estimation of the drug
in its formulation.9 This reported method depends onmeasurement of RFL at its kmax 248 nm in methanol. Recov-
ery data obtained from the developed HPLC-DAD method
were statistically compared with those of the comparison
method using Student’s t- and the variance ratio F-tests. In
both tests, the calculated values did not exceed the theoretical
Table 6 Application of the proposed HPLC-DAD method to
the analysis of RFL in its dosage form (Dalivent tablets).
External
standard
Reference
methodb
Standard
addition
% Recovery ± SDa 100.51 ± 0.44 99.75 ± 0.83 99.01 ± 0.47
RSD% 0.44 0.83 0.48
t 1.81
F 3.56
Theoretical values for t and F at P= 0.05 are 2.31 and 6.39,
respectively.
a Mean ± standard deviation for ﬁve determinations.
b Ref. 9.
HPLC-DAD method for determination of the phosphodiesterase (PDE-4) inhibitor roﬂumilast 89ones at the 95% conﬁdence level which indicated that there
were no signiﬁcant differences between the recoveries obtained
from both methods (Table 6). It is evident from these results
that the proposed method is applicable to the assay of RFL
in tablets with minimum sample preparation and satisfactory
level of accuracy and precision.
4. Conclusion
This study described a simple, selective and reliable HPLC-
DAD procedure for the assay of roﬂumilast in tablet dosage
form. To the best of our knowledge, this is the ﬁrst HPLC
report describing the quantiﬁcation of RFL in its tablet dosage
form. The described method is superior to the previously
reported non-selective UV spectrophotometric method for
tablets assay.9 A signiﬁcant advantage in the study is the
separation of RFL from several degradation peaks obtained
by hydrolytic, oxidative, photolytic and thermal forced
degradation experiments. In addition, speciﬁcity was further
demonstrated by separation of the analyte from several
pharmaceutical compounds of different pharmacological cate-
gories. The described method is advantageous to the previ-
ously reported HPLC methods7,8 since the proposed method
involves the use of simple isocratic elution compared to the
multi-step gradient elution of these previous methods.7,8 In
addition the proposed method was able to resolve roﬂumilast
in about 6 min compared to the published methods that
required about 13 min runtime.7,8 The previous stability-indi-
cating study reported obvious degradation of RFL in only
alkaline medium,7 while this current study demonstrates the
signiﬁcant degradation of the drug in acidic, alkaline and
oxidative conditions. Reliability was guaranteed by testing var-
ious validation parameters of the method and the successful
application to commercial tablet dosage form. The method
can thus be used for routine analysis, quality control, andfor checking quality during stability studies of pharmaceutical
preparations containing the drug.
5. Conﬂict of interest
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